Medis Medical Imaging Systems BV appears in FDA device records as the applicant behind QGuideCT (1.0), submitted under product code QIH and regulation number 892.2050 for automated radiological image processing software. The submission was received on February 17, 2026 and decided on October 5, 2026 as substantially equivalent under a traditional review. Company-published material describes QGuideCT as software that analyzes existing coronary CT angiography and renders three-dimensional views of the coronary tree. [1][4]
The documented FDA filing
The supplied collection holds one linked record, a 510(k) with a single substantially equivalent decision; the record sample contains the same single entry, K260523 for QGuideCT (1.0). The filing lists Medis Medical Imaging Systems BV as applicant, a Leiden, Netherlands address, product code QIH, device class 2, regulation 892.2050, advisory committee Radiology, and a traditional clearance type with a statement rather than a summary. [1]
The FDA premarket notification database pages for K260523 carry the standard navigation and language-access material for the 510(k) database; they do not add device-specific detail beyond the record itself. [2][3]
What QGuideCT is described to do
Medis-published release material describes QGuideCT as a automated analysis performed on existing coronary CTA, extracting and labeling the coronary tree including main epicardial vessels and side branches, and rendering a 3D reconstructed visualization of analyzed vessels. The same page lists four components: coronaries with synchronized views and editable vessel labeling, per-vessel plaque analysis with contour control, a cath lab viewer for 3D coronary reconstruction and quantitative plaque, and reporting with manual CAD-RADS 2.0 plaque reporting, total plaque volume and PDF and DICOM export. [4]
That release states QGuideCT 1.0 has received US market clearance from the FDA and that CE certification is pending, with the device not for clinical use in the EU. QGuideCT is identified there as a registered trademark of Medis Associated BV, a different legal entity from the FDA applicant. [4]
Company context and related products
Medis-published site material states that the company has developed cardiac imaging software for more than thirty years across CT, MRI, X-ray and ultrasound, aimed at cardiologists, radiologists, researchers and industry partners. A separate Medis page names QFR among its portfolio products supporting angiography-derived physiology in the cath lab. [7][6]
Medis-published commentary on the P4 trial, presented at TCT 2026, states that Medis QGuideCT is now FDA-cleared and describes the trial as comparing PCI planned with CT guidance against IVUS guidance. A second Medis commentary covers PIONEER IV final results on angiography-derived physiology. These are company statements about trial presentations, not FDA findings. [6][9]
An FDA establishment registration and device listing page identifies an establishment under the name MEDIS MEDICAL IMAGING; the supplied excerpt does not tie specific listed devices to the applicant. A Medis quality and regulatory page carries a quality policy statement about cardiovascular software and a regulatory contact address. [5][8]
